Search

everythinglearnresearchcommunity

for

Search:↓

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

Prostate cells have proteins that bind to specific hormones, which can increase protein production when activated by these hormones.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

New method finds genetic links between Type 2 Diabetes and Prostate Cancer not seen before.

Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.

CAG repeat polymorphism and prostate zone volume are not reliable markers of long-term androgen sensitivity.

Finasteride reduces prostate cancer risk but may affect ejaculatory volume and requires careful consideration for young men.

The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.

Men who start losing hair at age 30 may have a lower risk of prostate cancer.

Baldness at age 40 is not linked to a higher risk of aggressive prostate cancer.

Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.

Low-dose bisphenol A increases prostate size in rats by affecting certain enzymes.

Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Metformin may lower PSA levels, possibly affecting prostate cancer development.

Men with male pattern baldness have a higher risk of dying from prostate cancer.

MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.

The activity of a specific rat enzyme in the prostate and epididymis is highly dependent on the acidity level.

Platelet-rich plasma can improve erectile function in older individuals by reducing prostate enlargement.

Early balding, especially frontal, increases prostate cancer risk; more research needed.

% free PSA and urinary markers help better identify prostate cancer.

Testosterone replacement therapy, especially intramuscular, raises PSA levels, but no overall link between PSA and testosterone was found except in non-BPH patients.

Hair loss gene linked to prostate issues.

Androgen deprivation therapy doesn't lower the risk of death from COVID-19 in prostate cancer patients.

Men with vertex baldness may have a higher risk of developing prostate cancer, but more research is needed to confirm this.

Higher DHT in male baldness may protect against prostate cancer.

Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.

Prostate size varies by ethnic group, age, residence, and blood glucose, but not by body measurements or fat.